Omeprazole is a potent gastric antisecretory agent with selective inhibitory effect on the
H+,K+-ATPase proton pump. It is highly effective in the treatment of duodenal ulcer and
Zollinger-Ellison syndrome, and is reportedly superior to ranitidine in the management of
reflux esophagitis.
Omeprazole was first approved by the FDA in 1989 in the form of extended-release capsules for the treatment of acid-related disorders. Brand name Prilosec, it was initially used over-the-counter (OTC) for adults to help control heartburn that occurs two or more days a week.
Omeprazole is a proton pump inhibitor used to treat diseases like gastroesophageal reflux disease (GERD), used for gastric and duodenal ulcers, reflux or erosive esophagitis, and Zollinger-Ellison syndrome. It is also effective for gastric and duodenal ulcers that are ineffective with H2 receptor antagonists. Injections of Omeprazole can also be used for: 1 gastrointestinal bleeding, such as peptic and anastomic ulcer bleeding, and the prevention of severe diseases (such as cerebral hemorrhage, severe trauma, etc.) and gastric surgery caused by upper intestinal bleeding; 2 acute gastric mucosal damage complicated by stress or nonsteroidal anti-inflammatory drugs; 3 general anesthesia, post-surgery, or coma patients, to prevent acid reflux and aspiration pneumonia; 4 Combined with amoxicillin and clarithromycin, or with metronidazole and clarithromycin, it can effectively kill Helicobacter pylori (Hp).
Omeprazole is a benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors. Omeprazole Pellets are used in the treatment of Gastroesophageal reflux disease (GERD): A condition in which backward flow of acid from the stomach causes heartburn and injury of the food pipe (esophagus).
ChEBI: Omeprazole is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
The antiulcer agent omeprazole is produced from 2,3,5-trimethylpyridine N-oxide.
Synthesis and Structure of Omeprazole
Steps: 2-(Lithium methyl sulphinyl)-5-methoxy-1H benzimidazole 20g was reacted with 2-chloro-3,5-dimethyl-4-methoxy pyridine 21 g to form sulphide intermediate and then converted to Omeprazole when treated with m-CPBA which used as anoxidizingagents. The acetamide-sulfide compounds modification are oxidised to form the amide sulfinyl compound and gives the sulfinyl carboxylate or salts upon alkaline hydrolysis.On further decarboxylation leads to the target molecules. The residual, unreacted salt, inorganic by-products and other minor by-products can be easily purified by a simple washing from omeprazole or lansoprazole. The amide compounds containing crystalline solids as opposed to the sulphide and sulfoxides of the reported procedures.
DOI: http://dx.doi.org/10.20902/IJPTR.2019.120307
World Health Organization (WHO)
Omeprazole was introduced in the 1980s. It belongs to a group of
agents that have an inhibitory effect on the secretion of hydrochloric acid in the
stomach (gastric acid proton pump inhibitors) and is used in the treatment of
upper gastrointestinal tract disorders. The Committee for Proprietary Medicinal
Products of the European Commission has concluded that a causal association
between the reactions reported in Germany and the use of omeprazole had not
been established. Nevertheless oral administration should be preferred.
(Reference: (CPMPPO) Pharmacovigilance Opinion, No.16 , , 25 July 1994)
Omeprazole, 5-methoxy-2-(((4-methoxy-3, 5-dimethyl-2-pyridinyl)methyl) sulfinyl)-1Hbenzimidazole(Losec), is a white to off-white crystallinepowder with very slight solubility in water. Omeprazole isan amphoteric compound (pyridine N, pKa 4.06; benzimidazoleN-H, pKa 0.79), and consistent with the proposedmechanism of action of the substituted benzimidazoles, isacid labile. Hence, the omeprazole product is formulatedas delayed-release capsules containing enteric-coatedgranules.
The absolute bioavailability of orally administeredorneprazole is 30% to 40% related to substantial first-passbiotransformation. The drug has a plasmahalf-life of about 1 hour. Most (77%) of an oral dose ofomeprazole is excreted in the urine as metabolites with insignificantantisecretory activity. The primary metabolitesof omeprazole are 5-hydroxyomeprazole (CYP2C19) andomeprazole sulfone (CYP3A4). The antisecretory actions ofomeprazole persist for 24 to 72 hours, long after the drughas disappeared from plasma, which is consistent with itssuggested mechanism of action involving irreversible inhibitionof the proton pump.
Omeprazole is approved for the treatment of heartburn,GERD, duodenal ulcer, erosive esophagitis, gastric ulcer,and pathological hypersecretory conditions.
H + ,K + -ATPase inhibitor (IC 50 = 5.8 μ M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC 50 = 0.16 μ M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacteral against Helicobacter pylori in vitro . Also inhibits CYP2C19, CYP2C9 and CYP3A (K i values are 3.1, 40.1 and 84.4 μ M respectively) and blocks swelling-dependent chloride channels (ICIswell).
Omeprazole binds covalently to proton pump (H+, K+-ATPase) and inhibits gastric secretion. It is useful in ameliorating the effects of peptic oesophagitis, duodenal and gastric ulcer. Omeprazole is preferred over antagonists of histamine H2-receptor and ranitidine for its higher efficiency. It is also useful in treating Zollinger-Ellison syndrome.
Omeprazole is a proton-pump inhibitor used in the management and treatment of several conditions, including uncomplicated heartburn, peptic ulcer disease, gastrointestinal reflux disease, Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis, erosive esophagitis, gastric ulcers, and helicobacter pylori infection.
The aforementioned adverse
events published as case reports seem to be extremely
rare relative to the large number of treatment
courses with omeprazole of well above
100 million. Some of these adverse effects, however,
disappeared upon cessation of omeprazole
therapy and reappeared upon rechallenge
suggesting a causal relationship. These include
cases of myopathy , neuromyositis , erythema
nodosum , arthralgia , pityriasis
rosea-like skin eruption , hemolytic anemia
, interstitial nephritis , , CNSsymptoms
, , and acute gout .
Veterinary Drugs and Treatments
Omeprazole is potentially useful in treating both gastroduodenal
ulcer disease and to prevent or treat gastric erosions caused by
ulcerogenic drugs (e.g., aspirin). An oral paste product is labeled
for the treatment and prevention of recurrence of gastric ulcers in
horses.
Potentially hazardous interactions with other drugs
Anticoagulants: effect of coumarins possibly
enhanced.
Antiepileptics: effects of phenytoin possibly
enhanced.
Antifungals: absorption of itraconazole and
ketoconazole reduced; avoid with posaconazole;
concentration increased by voriconazole.
Antivirals: reduced atazanavir concentration
- avoid; AUC of saquinavir increased by 82%
(increased risk of toxicity) - avoid; concentration of
raltegravir possibly increased - avoid; concentration
of rilpivirine reduced - avoid; concentration of
omeprazole reduced by tipranavir.
Ciclosporin: variable response; mostly increase in
ciclosporin level.
Cilostazol: increased cilostazol concentration -
reduce cilostazol dose.
Clopidogrel: avoid due to reduced efficacy of
clopidogrel.
Cytotoxics: possibly reduced excretion of
methotrexate; avoid with erlotinib and vandetanib;
possibly reduced dasatinib and lapatinib absorption
- avoid with dasatinib; possibly reduced absorption
of pazopanib.
Tacrolimus: may increase tacrolimus concentration.
Ulipristal: reduced contraceptive effect, avoid with
high dose ulipristal.
When male humans are given 14C-omeprazole orally,
an average of 79% of the dose is recovered in the
urine in 96 h. Omeprazole is completely metabolized
and at least six metabolites are identified. Two major
metabolites are hydroxyomeprazole and omeprazole
acid.
Omeprazole is completely metabolised in the liver by the
cytochrome P450 system to form inactive metabolites
which are excreted mostly in the urine and to a lesser
extent in bile. CYP2C19 produces hydroxyomeprazole,
the major metabolite, CYP3A4 produces omeprazole
sulphone.
Omeprazole is a proton pump inhibitor which can specifically act on gastric parietal cell proton pump sites and transform into the active form of sulfonamide, then irreversibly binds to the proton pumps through disulfide bonds, generating a sulfonamide and proton pump compound (H + -K + -ATP), thereby inhibiting the enzymatic activity, preventing the H+ in parietal cells from being transported to the stomach cavity. It has a strong and persistent inhibitory role on gastric acid secretion caused by basal gastric acid and pentapeptide gastric acid secretions, greatly reducing gastric acid within the gastric juice. Rapid, reversible, and no H2 antagonist-induced psychiatric side effects.
[1] H SATOH. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.[J]. Journal of Pharmacology and Experimental Therapeutics, 1989, 248 2: 806-815.
[2] MAXIM KUZIN. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.[J]. Clinical Pharmacokinetics, 2018, 57 6: 729-737. DOI:
10.1007/s40262-017-0591-8[3] ANDREAS SCHMARDA. The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels[J]. British Journal of Pharmacology, 2009, 129 3: 598-604. DOI:
10.1038/sj.bjp.0703070[4] YUKO MAEJIMA . Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake[J]. Peptides, 2020, 128: Article 170312. DOI:
10.1016/j.peptides.2020.170312[5] SUSAN M WATANABE. Selective Targeting of Virus Replication by Proton Pump Inhibitors.[J]. ACS Applied Electronic Materials, 2020: 4003. DOI:
10.1038/s41598-020-60544-y[6] D. BOJKOVA. SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles[J]. bioRxiv : the preprint server for biology, 2020, 30 1. DOI:
10.1101/2020.04.03.024257
